Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.

Hyung-Joo Oh Suk-Chul Bae In Jae Oh Cheol-Kyu Park Kyoung-Mi Jung Da-Mi Kim Jung-Won Lee Chang Kyun Kang Il Yeong Park Young-Chul Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The addition of nicotinamide with EGFR-TKIs demonstrated potential improvements in PFS and OS, with notable survival benefits for female patients and those who had never smoked (ClinicalTrials.gov Identifier: NCT02416739).

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
end stage renal disease
clinical trial
ejection fraction
newly diagnosed
chronic kidney disease
double blind
phase iii
study protocol
peritoneal dialysis
phase ii
patient reported outcomes
combination therapy
replacement therapy
climate change